On the 31st, Sharperon announced that it had submitted an investigational new drug (IND) application to the US Food and Drug Administration to conduct a Phase II trial in the U.S. for its atopic dermatitis treatment, ‘NuGel.’

The company plans to evaluate the pharmacokinetics, safety, tolerance, and efficacy of NuGel through the multinational Phase II trial on patients with mild-to-moderate atopic dermatitis. Participants will be double-blinded and receive a placebo or NuGel for 8 weeks.

Through this clinical trial, Shaperon seeks to confirm NuGel’s improvement in eczema area and severity index (EASI score)) compared to placebo in patients with atopic dermatitis.

NuGel